Condition
Unresectable HER2-Negative Breast Carcinoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
3 shownTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07
RECRUITINGTesting the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast CancerNCT06590558 · 2025-08-04
WITHDRAWNOlaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment TrialNCT05967286 · 2023-10-23
WITHDRAWNCommon interventions
Biospecimen CollectionPROCEDURE3Computed TomographyPROCEDURE3Magnetic Resonance ImagingPROCEDURE3AlpelisibDRUG2Biopsy ProcedurePROCEDURE2Bone ScanPROCEDURE2OlaparibDRUG2Positron Emission TomographyPROCEDURE2BinimetinibDRUG1BiopsyPROCEDURE1Bone Marrow AspirationPROCEDURE1Bone Marrow BiopsyPROCEDURE1Echocardiography TestPROCEDURE1Eribulin MesylateDRUG1FluorouracilDRUG1FulvestrantDRUG1IpatasertibDRUG1LeucovorinDRUG1Multigated Acquisition ScanPROCEDURE1Mutation Carrier ScreeningPROCEDURE1Neratinib MaleateDRUG1Nilotinib Hydrochloride MonohydrateDRUG1OxaliplatinDRUG1PaclitaxelDRUG1PalbociclibDRUG1
Leading sponsors
Trial status mix
WITHDRAWN2
RECRUITING1
Phase mix
PHASE22
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.